Stockscreener 앱 받기
0.00
100.00%
-5.00
2 Seventy Bio Inc 주식(TSVT)의 최신 뉴스
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades - Managed Healthcare Executive
Cigna Launches AI Tools to Simplify Health Insurance, Improve Customer Experience - Managed Healthcare Executive
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC - Managed Healthcare Executive
Alachua bio-manufacturing plant to lay off employees ahead of shutdown - WCJB | TV20
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
Wellington Management Group LLP Reduces Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
BNP Paribas Financial Markets Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Deutsche Bank AG Has $1.10 Million Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
MHE Week in Review –Medicaid Bill Mayhem, UnitedHealth’s Stock Plummets and More - Managed Healthcare Executive
Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Investor relations - Bristol Myers Squibb
Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio completes merger with Bristol-Myers Squibb - Investing.com
Earnings call transcript: Nuvation Bio Q1 2025 sees strategic focus amid EPS miss - Investing.com India
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
Stelara Biosimilar Yesintek Gains Coverage on Leading Formularies - Managed Healthcare Executive
Yearly Depression Screening for Young Adults Is Worth the Cost - Managed Healthcare Executive
Brokerages Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $5.60 - Defense World
Updated: UnitedHealth Group’s First Quarter Revenue Increases, But Company Revises Outlook - Managed Healthcare Executive
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc.TSVT - Business Wire
Neuroscientific to Acquire Leading Stem Cell Technology - Investing News Network
American Century Companies Inc. Boosts Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Liver Injury Ends Development of Pfizer’s Oral GLP-1 for Obesity - Managed Healthcare Executive
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
FDA Approves Biocon’s Avastin Biosimilar - Managed Healthcare Executive
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $6.67 - Defense World
Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Intech Investment Management LLC - The AM Reporter
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
FDA Approves Cabometyx to Treat Advanced Pancreatic Cancer - Managed Healthcare Executive
Nonopioid Pain Drug Journavx Gaining Traction With High Potential - Managed Healthcare Executive
Novo Nordisk Extends Lowered Wegovy Price to Retail Pharmacies - Managed Healthcare Executive
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G - Managed Healthcare Executive
Should MAHA Tackle the Chronic Disease Epidemic with Preventative Care? - Managed Healthcare Executive
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
For Pfizer, Some Challengers in ATTR-CM Treatment - Managed Healthcare Executive
Fresenius Kabi Launches Otulfi, the 4th Biosimilar of Stelara to Become Available - Managed Healthcare Executive
FDA Accepts sNDA for Zoryve Cream for Atopic Dermatitis Treatment in Young Children - Managed Healthcare Executive
Second Biosimilar of Stelara Launches - Managed Healthcare Executive
FDA Approves First Biosimilar of Novolog - Managed Healthcare Executive
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar - Managed Healthcare Executive
FDA Approves Second Biosimilars for Prolia/Xgeva - Managed Healthcare Executive
0.79%
0.99%
자본화:
|
볼륨(24시간):